BGI Genomics Co., Ltd. — Investor Relations & Filings
BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 第四届董事会第五次会议决议公告 | 2025-04-25 | Chinese | |
| 2024年年度财务报告 | 2025-04-25 | Chinese | |
| 2024年度独立董事述职报告(杜兰) | 2025-04-25 | Chinese | |
| 关于召开2024年年度股东会的通知 | 2025-04-25 | Chinese | |
| 关于举行2024年度网上业绩说明会的公告 | 2025-04-25 | Chinese | |
| 关于作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票的公告 | 2025-04-25 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2025
15 filings
| |||||
| 38371514 | 第四届董事会第五次会议决议公告 | 2025-04-25 | Chinese | ||
| 38371481 | 2024年年度财务报告 | 2025-04-25 | Chinese | ||
| 38371442 | 2024年度独立董事述职报告(杜兰) | 2025-04-25 | Chinese | ||
| 38371425 | 关于召开2024年年度股东会的通知 | 2025-04-25 | Chinese | ||
| 38371413 | 关于举行2024年度网上业绩说明会的公告 | 2025-04-25 | Chinese | ||
| 38371403 | 关于作废2022年限制性股票激励计划部分已授予尚未归属的限制性股票的公告 | 2025-04-25 | Chinese | ||
| 38371387 | 2024年度募集资金存放与使用情况专项鉴证报告 | 2025-04-25 | Chinese | ||
| 38371370 | 关于2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属条件成就的公告 | 2025-04-25 | Chinese | ||
| 38371352 | 关于调整2022年限制性股票激励计划授予价格的公告 | 2025-04-25 | Chinese | ||
| 38371319 | 2024年年度报告摘要 | 2025-04-25 | Chinese | ||
| 38371309 | 国浩律师(深圳)事务所关于深圳华大基因股份有限公司2022年限制性股票激励计划之授予价格调整、归属条件成就及部分限制性股票作废事项的法律意见书 | 2025-04-25 | Chinese | ||
| 38371288 | 关于2025年度公司及子公司向银行等金融机构申请综合授信额度的公告 | 2025-04-25 | Chinese | ||
| 38371277 | 2024年度营业收入扣除情况专项说明 | 2025-04-25 | Chinese | ||
| 38371267 | 监事会关于2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属名单的核查意见 | 2025-04-25 | Chinese | ||
| 38371251 | 公司章程(2025年4月) | 2025-04-25 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
BGI Genomics Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/55655/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=55655 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=55655 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=55655 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 55655}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for BGI Genomics Co., Ltd. (id: 55655)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.